Detalles de la búsqueda
1.
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
Ann Hematol;
2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38568260
2.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol;
2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38438627
3.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer;
22(1): 1013, 2022 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36153475
4.
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Blood Cancer J;
11(2): 21, 2021 02 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33563901
5.
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Leukemia;
35(2): 485-493, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33414483
6.
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Lancet Haematol;
7(8): e601-e612, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32563283
Resultados
1 -
6
de 6
1
Próxima >
>>